Insider Selling: uniQure (NASDAQ:QURE) Insider Sells 3,412 Shares of Stock

Key Points

• Insider selling: Director Jeannette Potts sold 3,412 shares at an average price of $9.06 on March 4, reducing her stake by 2.4% to 138,483 shares, and multiple other insiders (including the CEO and CFO) also sold stock that day.
• Regulatory setback and market reaction: A senior FDA official publicly called uniQure’s Huntington’s‑disease gene therapy unsuccessful and asked for a new randomized, placebo‑controlled study, sparking broad media scrutiny, class‑action notices and a roughly 32% one‑week stock plunge.
• Company and analyst context: uniQure slightly beat quarterly EPS and revenue estimates but remains deeply unprofitable with negative margins; Wall Street consensus is a "Hold" (average target ~$34.33) amid high share price volatility (52‑week range $7.76–$71.50).

uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Jeannette Potts sold 3,412 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the sale, the insider directly owned 138,483 shares of the company's stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

uniQure Stock Performance

Shares of QURE traded up $3.62 during mid-day trading on Friday, reaching $14.27. 16,602,429 shares of the company's stock were exchanged, compared to its average volume of 3,442,688. The business's fifty day simple moving average is $22.25 and its 200-day simple moving average is $29.44. The stock has a market capitalization of $892.30 million, a PE ratio of -4.14 and a beta of 0.73. uniQure N.V. has a 52-week low of $7.76 and a 52-week high of $71.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million during the quarter, compared to analysts' expectations of $4.84 million. On average, equities research analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

Wall Street Analyst Weigh In

A number of research firms have weighed in on QURE. William Blair reaffirmed a "market perform" rating on shares of uniQure in a research report on Tuesday, November 11th. Barclays started coverage on uniQure in a report on Tuesday, January 27th. They set an "equal weight" rating and a $31.00 price target for the company. Wolfe Research initiated coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a "peer perform" rating on the stock. Stifel Nicolaus set a $14.00 target price on shares of uniQure in a research note on Monday. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $34.33.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP acquired a new position in shares of uniQure during the 4th quarter worth approximately $209,000. Virtus Investment Advisers LLC increased its position in uniQure by 91.6% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company's stock worth $326,000 after purchasing an additional 6,520 shares in the last quarter. SummitTX Capital L.P. raised its stake in uniQure by 386.3% in the 4th quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company's stock valued at $663,000 after purchasing an additional 22,010 shares during the last quarter. Suvretta Capital Management LLC purchased a new position in uniQure in the 4th quarter valued at about $29,116,000. Finally, Readystate Asset Management LP acquired a new stake in shares of uniQure during the 4th quarter worth about $8,652,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.